06 diciembre 2014

Scientists have discovered that the reefs contain an abundance of micro-organisms and compounds produced by those organisms not found anywhere on earth. Many of these compounds show promise in holding cures for some of our most common and serious ailments including cancer.

Reef may hold treatments, even cures, for serious diseases .


Keynoter Publishing December 5, 2014 .



... The list is impressive.



Blue-green algae, commonly found around Caribbean mangroves, is the source of a toxin that is being used to treat small-cell lung cancer and has been endorsed by the National Cancer Institute for the treatment of melanoma.

Yondelis, the first new treatment in 30 years for soft-tissue sarcoma, is extracted from the sea squirt, a sac-like filter feeder.

The spiral tufted bryozoan (Bugula neritina), a colonial animal that grows upright in bushy, branching tufts is a source for the anti-cancer compound bryostatin.

Secosteroids, an enzyme used by soft corals to protect themselves from disease, is used to treat asthma, arthritis and other inflammatory disorders.

Bioactive molecules produced by marine invertebrates such as sea sponges, tunicates and sea hares have displayed potent anti-viral, anti-tumor and antibacterial activity.

Certain marine-based medicines for the treatment of lymphoma and ovarian, breast and prostate cancers have gone through clinical trials.

Others show promise in the treatment of strokes and Alzheimer’s disease.

With just a few more years of research, it is likely that scientists will discover even more therapeutic secrets in the sea .

...

Sylentis ( Grupo Zeltia ) ya ha sido incluida en el último Informe sobre Espectativas en el Tratamiento de Demencias : "" Dementia Therapeutic Pipeline Market by Companies & Drugs Profile Review H2 2014 "" .

PRWEB.COM NewswireDallas, TX (PRWEB) December 06, 2014

The report "Dementia Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. Dementia is the loss of psychological features such as considering, storage, and considering that is serious enough to intervene with a person's everyday performing.


Companies discussed in this Dementia Pipeline Review H2 2014 report include Alector LLC, Biotie Therapies Corp., Bristol-Myers Squibb Company, Chase Pharmaceuticals Corporation, Chronos Therapeutics Limited, Echo Pharmaceuticals B.V., FORUM Pharmaceuticals Inc., Hyundai Pharmaceutical Co., Ltd., Ildong Pharmaceutical Co., Ltd., ImStar Therapeutics Inc., Integrative Research Laboratories Sweden AB, Intellect Neurosciences, Inc., Intra-Cellular Therapies, Inc., Oryzon Genomics S.A., Pacific Northwest Biotechnology, LLC, SK Chemicals Co., Ltd., Stelic Institute & Co., Summit Corporation plc, Sylentis S.A., Tautatis Incorporated, WhanIn Pharmaceutical Co., Ltd.

Drugs profile discussed in this Dementia Pipeline Review H2 2014 report include Antibodies for Dementia and Alzheimer's Disease, Antisense Oligonucleotide to Inhibit microRNA for Neurology, choline alfoscerate SR, CPC-252, dronabinol, Drugs to Agonize c-MET for Dementia, Drugs to Agonize c-MET for Dementia, FRM-0334, GIBH-130, gugulipid, IPN-007, IRL-752, ITI-007, KR-12, Monoclonal Antibodies to Inhibit Tau for CNS Disorders, NAT, NNC-269100, OG-635, Peptide to Inhibit BACE for Cerebropathy and Dementia, RDC-5, RNAi Oligonucleotide for Cerebral Ischemia and Dementia, SID-111, Small Molecule to Activate LPL for CNS and Metabolic Disorders, Small Molecule to Inhibit Glycogene 5 for Dementia, Small Molecule to Inhibit O-linked N-acetylglucosaminidase for Neurodegenerative Diseases, Synthetic Peptides for Neurological Disorders, TauC3 Monoclonal Antibody, TTT-3002 & WIB-1001C. Order a Purchase copy of this report @ .


... Informe : 2.000 $$ .